Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,137
Regeneron Pharma Is Maintained at Buy by Truist Securities
Express News | Regeneron Pharmaceuticals Inc : Truist Securities Cuts Target Price to $1137 From $1200
Jasper Gains 11% on Data for Briquilimab in Urticaria
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
The bull market in US stocks will enter its third year. The three major futures are mixed before the market. | Focus tonight.
nasdaq 100 index futures rose more than 0.4% in pre-market trading; Apple is set to launch a $2000 Vision headset as early as next year; Taiwan Semiconductor plans to establish more chip factories in europe; Glaxosmithkline's experimental drug for treating rhinitis showed positive results in clinical trials.
